bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
ANT10A

Order Name:
Anti-Factor Xa (Heparin)

 
Useful For:
Measuring heparin concentration in patients treated with low-molecular-weight heparin preparations
 
Methodology:
Chromogenic substrate
 
AliasesName:
Anti-10a
Anti-Xa
Heparin Anti-Xa Assay, Plasma
Lovenox (Enoxaparin)
Low-Molecular Weight Heparin Assay
Unfractionated Heparin Assay
 
 
 
Test Code:
ANT10A

Order Name:
Anti-Factor Xa (Heparin)

 
Collection Specimen Or Container:
Blood/ Sodium citrate tube (Sodium Citrate 3.2% anticoagulant, Blue top) 3 mL, 1 tube
 
Specimen Testing Type:
Citrate plasma, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: Hemoglobin > 300 mg/dL
Lipemia: Triglyceride > 800 mg/dL
Icterus: Bilirubin > 20 mg/dL
Other: Clotted specimen will be rejected.
 
Specimen Stabillity:
Specimen Type Temperature Time
Platelet-poor plasma Room temperature, 18oC to 25oC 1 hour
Refrigerated, 2oC to 8oC 4 hours
 
 
 
Test Code:
ANT10A

Order Name:
Anti-Factor Xa (Heparin)

 
Method detail:
Chromogenic substrate
 
Schedule:
Tested Daily (24 hours)
 
Turnaround Time:
Collected specimen to report within 1.5 hours (90 mins)
 
Performing Location:
Hematology, Laboratory Department Tel. 17254
 
Specimen Retention Time:
14 days
 
 
 
Test Code:
ANT10A

Order Name:
Anti-Factor Xa (Heparin)

 
 
Clinical Information:
Heparins are sulphated glycosaminoglycans that inactivate thrombin, factor Xa, and several other coagulation factors. Act by enhancing activity of the plasma coagulation inhibitor, antithrombin III (AT III) and prolong the activated partial thromboplastin time (APTT). The anti-Xa assay is the preferred method for monitoring low-molecular-weight heparin (LMWH) therapy because of reduced sensitivity of APTT. Heparin is absent in normal plasma. The heparin level obtained has to be analyzed taking into account the treatment given to the patient (type of heparin, dosage, administration mode, time of sampling, etc) and the desired therapeutic effect. It is clinically recommended that platelet counts be monitored frequently in patients receiving unfractionated heparin (UFH) or LMWH in order to detect heparin-induced thrombocytopenia (HIT).
 
Clinical Reference:
  1. Manufacturer’s reagent package insert, Liquid Anti-Xa, HemosIL®, Instrumentation Laboratory Company - Bedford, MA 01730-2443 (USA), Instrumentation Laboratory SpA - V.le Monza 338 - 20128 Milano (Italy), 02/2016
  2. https://www.mayocliniclabs.com (Retrieved: 22 Jan 2019)